Zielsetzung
The EU GMP Conference is only offered every two years. This unique conference will discuss current and planned changes to the GMP regulation. All experts and managers involved in GMP compliance activities will have the opportunity to get a comprehensive GMP update and to talk to the leading experts from industry and authority.
Although EU GMP is in the center of attention, a harmonized approach with cGMP from FDA will also be an important aspect of the agenda. For international operating companies both EU GMP and FDA compliance is important and the corporate quality systems need to cover the regulation of both regions.
The agenda will therefore focus on key GMP compliance developments. Attention will be paid on the implementation of these requirements into pharmaceutical quality systems. The ECA Foundation’s objective is to support industry, and therefore current activities as well as guidance documents and SOPs are presented during this conference.
Each Session will have speakers from industry and inspectorates to discuss both expectations and implementation aspects.
We wish you a successful and interesting conference.
Yours sincerely,
Richard M. Bonner
Chairman of the ECA Advisory Board
Zielgruppe
The conference is of particular interest for GMP experts of pharmaceutical companies (e.g. QA, QC, production, distribution, regulatory affairs, validation), of GMP inspectorates and Regulatory Authorities.
Only at this conference - Additional ECA Guidance documents for all participants
ECA Guidance Document on Data Integrity
ECA Guidance Document on OOE and OOT
ECA Good Practice Guide on Validation Version 02
ECA/PQG Guide on Good Distribution Practice
Programm
Gesamtes Programm als PDF herunterladen
Session I Current Initiatives in EU and FDA
This session will discuss the latest changes and current initiatives in EU GMP and FDA GMP regulation
Update from recent EU GMP changes
- Latest Changes in EU Regulations
- Latest Revisions of the EU GMP Guide and its Annexes
- New EM Guidelines with impact to GMPs
- Look over the Pond - Important GMP developments in the US
Doing business with companies that operate outside of the EU/FDA zones
- How do I know if the company is producing using equivalent GMPs
- Do cultural differences matter?
- How will I know if anything goes wrong?
- What if I am purchasing through a broker?
- What is my QP responsible for?
Data Integrity is one of the top topics since some years. Data Integrity is not very detailed described in the EU GMP Guide. So some national authorities (e.g. MHRA) published interpretations about Data Integrity. Also the FDA has published a Guideline on it. The current status regarding Data Integrity is discussed in this session.
GMP Inspections and Data Integrity – Typical Pitfalls
- MHRA´s Data Integrity Guideline
- Authorities expectations
- Inspection findings
- Training as a QA Tool
- The special case: Data Integrity Training
- Case Study
- Overview of Data Integrity Interest Group
- Generation process of this guidance document
- Structure and content
- Current status and next steps
In FDA Warning Letters the lack of Quality Oversight is often mentioned. How is this been seen from an European perspective? Could the FDA requirement on FDA Quality Metrics could also be used as indicator for quality oversight? These questions will be discussed in this session.
Measuring and Monitoring of Quality Assurance: Regulatory Expectations
- Legal requirements – EU and international
- Links to ICH Q8, Q9 and Q 10 - Quality oversight
- Authority requirements
- Examples
- Building Quality Culture
- Use of existing Systems
- Benefits from using KPI Implementation in a pharmaceutical company
- Regulatory expectations
- Case Study
In the movement of the GMPs in the last years one development could be seen. More focus on statistics. This concerns also sampling. On the other hand industry wants to reduce sampling as sampling is costly. An EU inspector will give an overview about (statistical) GMP sampling requirements and an Industry representative will give practical information regarding reduced sampling.
Sampling – View of an EU GMP Inspector
- API and finished goods sampling und testing
- EU GMP Guide sampling requirements
- Part 1, Chapters 4, 5, 6
- Part 2, Chapter 7
- Annexes
- Other regulations
- US / FDA Requirements
- Supplier qualification and audits
- Reduced testing
- Statistical sampling
- Findings
Sampling plans
- How to define sample size for APIs
- Excipients
- Primary Packaging Material
- Secondary Packaging Material
- When can sampling be reduced?
- How to deal with deviations?
Get involved in the ECA Working Groups. Each delegate will be invited to discuss the upcoming developments with the Chair/Co-Chairs of the working groups.
Agenda
You can address topics of interest for you and you can provide feedback on the currently planned activities. It is the aim of the Working Group to provide a platform of discussion with both colleagues from industry and regulatory authorities.
Dieses Seminar/Webinar kann nicht gebucht werden. Alternative Termine für dieses Seminar/Webinar und ähnliche Veranstaltungen finden Sie in der Liste aller Seminare.
Für viele Seminare und Webinare gibt es auch Aufzeichnungen, die Sie jederzeit bestellen und anschauen können. Diese Aufzeichnungen finden Sie in der Liste aller Aufzeichnungen.
Oder senden Sie uns Ihre Anfrage einfach über das folgende Kontaktformular.
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen - das sagen andere über unsere Seminare:
